This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Intracerebral haemorrhage뇌내출혈

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: I61 (intracerebral haemorrhage) | Special Copayment Reduction: V191 (Special Copayment Reduction for cerebrovascular disease: 5% copayment for up to 30 days from the registration date)
B. SynonymsIntraparenchymal hemorrhage, spontaneous intracerebral hemorrhage (sICH), hypertensive cerebral hemorrhage
C. Adult onsetIncidence rises sharply after age 55, and hypertension is the major risk factor. In the elderly, cerebral amyloid angiopathy (CAA) emerges as an important cause.
1. HistorySince Wepfer's first clinicopathological description in the 17th century, the introduction of CT (1974) and the 2022 AHA/ASA guideline revision are the major milestones in the history of diagnosis and treatment.
2. CausesHypertension is the most common cause; cerebral amyloid angiopathy, anticoagulant use, vascular malformations, and hematologic disorders are other major causes.
3. GeneticsThe APOE ε4 allele is associated with CAA-related intracerebral hemorrhage, and GWAS have reported dozens of susceptibility loci.
4. General epidemiologyThe global annual incidence is about 24.6 per 100,000, and incidence in Asian populations is more than twice that in Western populations.
5. PathophysiologyHematoma formation after small-vessel rupture, perihematomal cytotoxic edema, blood-brain barrier disruption, and neuroinflammatory responses cause secondary injury.
6. SymptomsCharacterized by sudden-onset hemiparesis, speech disturbance, headache, and decreased consciousness; the clinical picture is determined by the location of the hemorrhage.
7. SignsMotor deficits, visual field defects, sensory disturbances, ocular motor abnormalities, and decreased GCS appear specifically according to the location of the hemorrhage.
8. ScreeningEarly detection and treatment of hypertension is the key preventive strategy, and regular risk assessment is recommended for patients taking anticoagulants.
9. DiagnosisNon-contrast head CT is the first-line diagnostic test; MRI and CTA evaluate underlying vascular lesions and hematoma expansion.
10. TreatmentAcute blood pressure control, anticoagulation reversal, and intracranial pressure management are the main treatments, and surgical hematoma evacuation is performed in selected patients.
11. PrognosisThe 30-day mortality is about 40%; hematoma volume, accompanying intraventricular hemorrhage, and initial GCS are the major prognostic factors.
12. PreventionBlood pressure management, smoking cessation, moderation of alcohol intake, appropriate anticoagulant management, and glycemic control are key to preventing recurrence.
13. ReferencesGreenberg SM, et al. 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage. Stroke. 2022 … and 9 other papers

1. History

The history of intracerebral hemorrhage (ICH) dates back to the 17th century. In 1658, the Swiss physician Johann Jakob Wepfer first systematically described blood accumulation within the brain parenchyma at autopsy of patients who died of stroke, arguing that stroke is not always due to a single cause. Later, in the 18th century, Giovanni Morgagni built on Wepfer's observations, recorded numerous autopsy cases of cerebral hemorrhage, and established early concepts of the association between hypertension and stroke.

In the mid-19th century, Samuel Wilks (1859) and John Abercrombie described clinicopathologically cerebral hemorrhage caused by hypertensive vascular lesions. In the early 20th century, Harvey Cushing and others began exploring the possibility of removing intracerebral hematomas from a neurosurgical perspective, but surgical results were poor. The introduction of CT in the 1970s brought a revolutionary change to the diagnosis of intracerebral hemorrhage; in 1974, Ambrose and Hounsfield succeeded in noninvasively visualizing cerebral hematomas with CT, making antemortem diagnosis and precise localization possible.

In the 1980s–90s, advances in MRI and cerebral angiography refined the assessment of temporal changes in hematomas and of underlying vascular lesions. In 2005, the first STICH (Surgical Trial in Intracerebral Haemorrhage) study compared outcomes of early surgery and medical treatment in ICH patients and showed no major difference between medical treatment and surgery in slowly progressing hemorrhage, provoking considerable controversy over the direction of ICH treatment. A series of clinical trials, including the INTERACT study in 2008, demonstrated that aggressive acute blood pressure lowering (systolic target 140 mmHg) is effective in limiting hematoma expansion. The 2022 revised AHA/ASA intracerebral hemorrhage guideline reflects the latest evidence on anticoagulation reversal, blood pressure management, minimally invasive hematoma evacuation, and more, and has become the most comprehensive clinical guideline.


2. Causes

Causes of intracerebral hemorrhage are broadly classified as primary and secondary. Primary ICH accounts for about 78–88% of all cases, and hypertensive small vessel disease and cerebral amyloid angiopathy (CAA) are the main causes. In hypertensive ICH, lipohyalinosis and fibrinoid necrosis progress in small penetrating arteries such as the lenticulostriate arteries, leading to vessel rupture; it occurs most often in the basal ganglia, thalamus, pons, and cerebellum.

CAA is a condition in which beta-amyloid is deposited in the walls of cortical and leptomeningeal vessels, increasing vascular fragility, and is the main cause of lobar hemorrhage in the elderly. CAA-related ICH occurs most often at the cortical–subcortical junction, and cortical superficial siderosis and multiple cerebral microbleeds are characteristically observed on MRI.

Secondary ICH arises from a variety of causes, including cerebral arteriovenous malformation (AVM), cavernous malformation, cerebral venous sinus thrombosis, vasculitis, brain tumors (primary or metastatic), coagulation disorders, overdose of anticoagulants and antiplatelet agents, thrombolytic use, sympathomimetic stimulants such as cocaine, and moyamoya disease. In patients taking warfarin, the risk of ICH is increased about 8–11-fold compared with the general population, while direct oral anticoagulants (DOACs) carry a lower risk. During pregnancy and the postpartum period, eclampsia, thrombotic microangiopathy, and cocaine use act as special causes of ICH.


3. Genetics

The genetic contribution to intracerebral hemorrhage differs by cause. In CAA-related ICH, the APOE ε4 allele is the strongest genetic risk factor; in APOE ε4/ε4 homozygotes, CAA severity is markedly higher and the risk of ICH recurrence is increased. Conversely, the APOE ε2 allele is known to increase the risk of intraparenchymal vessel rupture. This is attributed to differences in amyloid clearance and vascular fragility among APOE isoforms.

Hereditary ICH syndromes also exist: CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) is caused by NOTCH3 gene variants and can cause ICH due to small vessel disease. CARASIL (cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy) is a recessive small vessel disease caused by HTRA1 gene variants. Cerebral cavernous malformation (CCM) is associated with variants in the CCM1 (KRIT1), CCM2 (MGC4607), and CCM3 (PDCD10) genes and shows familial occurrence.

Genome-wide association studies (GWAS) have reported dozens of loci associated with the occurrence of ICH. In hypertension-related ICH, polymorphisms in blood pressure regulation genes (CYP17A1, UMOD, etc.) contribute indirectly to ICH risk, while rare variants in the COL4A1 and COL4A2 genes, which are directly involved in cerebrovascular fragility, are associated with small-vessel rupture. Polymorphisms in coagulation factor genes (F5, F2, VKORC1) affect anticoagulant sensitivity and thereby indirectly modulate ICH risk.


4. General epidemiology

Intracerebral hemorrhage accounts for about 10–15% of all strokes but is one of the major causes of stroke-related death and disability. The global annual incidence is estimated at about 24.6 per 100,000 population (95% CI: 19.8–30.5), which is lower than that of ischemic stroke, but mortality is much higher. In particular, ICH incidence in East Asian populations (Korea, China, Japan) has consistently been reported to be about twice or more that in Western white populations, which is analyzed to be attributable to genetic predisposition together with differences in environmental factors such as hypertension prevalence, salt intake, and smoking rates.

According to Korean data, ICH accounts for about 18–22% of all strokes annually, a relatively higher proportion than in other countries, and analysis of nationwide health insurance claims data confirms that hypertensive ICH accounts for the largest share. Incidence rises sharply from age 55 and peaks in those aged 80 or older. The sex distribution is slightly higher in men, but the proportion of women increases over age 75. Overall, hypertensive ICH is decreasing somewhat owing to improved blood pressure control and widespread use of antithrombotic agents, whereas CAA-related ICH and anticoagulant-related ICH are increasing with population aging.

ICH incidence is known to be higher in groups of low socioeconomic status, which is related to poor hypertension management, higher smoking and drinking rates, and reduced access to medical care. African Americans have about a 2–3-fold higher risk of ICH than white Americans, and the age of onset is about 10 years earlier. These racial differences reflect differences in genetic factors and hypertension burden.


5. Pathophysiology

The pathophysiology of hypertensive ICH begins when chronic hypertension causes lipohyalinosis and fibrinoid necrosis in the walls of small penetrating arteries (50–200 μm in diameter), increasing their structural fragility, and the vessel ruptures during an abrupt rise in blood pressure. When blood enters the brain parenchyma, a hematoma forms, and hematoma expansion during the first few hours is the key mechanism of secondary injury. Hematoma expansion occurs in about 30–40% of ICH patients and is a major cause of neurological deterioration and poor prognosis.

After hematoma formation, the toxic effects of blood and its breakdown products on the surrounding brain tissue act as an important mechanism of secondary injury. Thrombin within the clot induces cytotoxicity and inflammatory responses, and heme and iron, breakdown products of hemoglobin, promote death of surrounding neurons and glial cells through oxidative injury. Cytotoxic edema develops early around the hematoma, followed by vasogenic edema due to disruption of the blood-brain barrier (BBB), which progresses over several days. Cerebral edema peaks about 5–7 days after hematoma formation and is a major cause of increased intracranial pressure and brain herniation.

Neuroinflammatory responses also play a key role in the injury process after ICH. Damage-associated molecular patterns (DAMPs) within the hematoma activate microglia and macrophages, followed by complement activation and secretion of cytokines (IL-1β, TNF-α, IL-6). These inflammatory responses initially contribute to hematoma clearance but, if sustained, cause additional neuronal injury. Infiltration of neutrophils and monocytes due to blood-brain barrier disruption amplifies the inflammatory response, and therapeutic strategies targeting it are currently under active investigation.


6. Symptoms

Intracerebral hemorrhage mostly occurs suddenly during activity (especially during physical activity or emotional excitement), and progression of symptoms over minutes to hours is more common than in ischemic stroke. Headache occurs in about 40–50% of ICH patients; caused by increased intracranial pressure, it is sudden in onset and severe. It is less characteristic than in SAH, but patients with accompanying intraventricular hemorrhage complain of more severe headache.

Characteristic neurological symptoms appear depending on the location of the hemorrhage. Basal ganglia (especially putaminal) hemorrhage is characterized by contralateral hemiparesis and hemisensory disturbance, with aphasia when the dominant hemisphere is involved. Thalamic hemorrhage features prominent sensory disturbance (especially reduced pain sensation), with characteristic ocular motor abnormalities (downward gaze deviation, Parinaud syndrome). Pontine hemorrhage is accompanied by bilateral pinpoint pupils, quadriplegia, loss of consciousness, and fever, and is highly lethal. Cerebellar hemorrhage is characterized by sudden severe headache, vomiting, gait ataxia, and dizziness; it can progress rapidly to loss of consciousness from brainstem compression and requires emergency treatment.

Nausea and vomiting accompany about 50% of ICH cases and are especially prominent in cerebellar and pontine hemorrhage. Decreased consciousness occurs to varying degrees depending on hematoma size and location and is assessed with the GCS. Early decreased consciousness is strongly associated with poor prognosis. Seizures occur in about 10–16% of ICH patients and are more common in subcortical or lobar hemorrhage. When intraventricular hemorrhage (IVH) is present, consciousness may deteriorate rapidly due to acute obstructive hydrocephalus.


7. Signs

Physical and neurological examination findings vary with the location of the hemorrhage and hematoma size. Among vital signs, hypertension is most commonly observed (systolic blood pressure of 180 mmHg or higher is common); this reflects underlying hypertension but is also part of the Cushing reflex (hypertension–bradycardia–respiratory irregularity) in response to increased intracranial pressure. Fever may appear as central fever in intraventricular or massive hemorrhage.

On neurological examination, motor deficits are the most common sign, with contralateral hemiparesis or paresis of the upper and lower limbs found to varying degrees depending on hematoma location. Ocular motor abnormalities, such as conjugate gaze deviation toward the hematoma, downward deviation (thalamic hemorrhage), pinpoint pupils (pontine hemorrhage), and ipsilateral pupillary dilation (herniation due to cerebellar hemorrhage), are important clues to the site of hemorrhage. Sensory disturbances are prominent in thalamic and parietal hemorrhage, with reduced or absent pain, temperature, and touch sensation on the contralateral side of the body.

In cerebellar hemorrhage, gait ataxia, limb ataxia, nystagmus, and dysarthria are characteristic. Neck stiffness may occur with intraventricular hemorrhage or involvement of the subarachnoid space. The ICH Score (GCS, hematoma volume, presence of intraventricular hemorrhage, infratentorial origin, age ≥80 years) is a widely used clinical tool for predicting 30-day mortality; the higher the score, the worse the prognosis.


8. Screening

Population-based screening for intracerebral hemorrhage is not currently recommended. However, early detection and treatment of hypertension, the most important modifiable risk factor for ICH, is effectively the key screening strategy for ICH prevention. Regularly measuring blood pressure in adults and actively treating hypertension when identified is known to be the most effective intervention for preventing ICH. Korean hypertension management guidelines also recommend blood pressure measurement every 2 years in adults aged 18 and older and annually in high-risk groups.

In patients taking anticoagulants, regular monitoring to maintain the INR within the therapeutic range is essential. In patients on warfarin whose INR frequently exceeds the therapeutic range, switching to a DOAC may be considered. In patients with nonvalvular atrial fibrillation taking a DOAC, bleeding risk (HAS-BLED score) and thromboembolic risk (CHA2DS2-VASc score) are regularly reassessed to decide whether to continue anticoagulation and which agent to choose. If thrombocytopenia or a coagulation disorder is suspected, evaluation by blood tests is necessary.

In groups at high risk for CAA (advanced age, Alzheimer disease, APOE ε4 carriers), screening for microbleeds using MRI gradient echo or susceptibility-weighted imaging (SWI) sequences is used for research purposes but has not yet been established in clinical guidelines. In patients with suspected familial cerebral cavernous malformation, genetic testing and brain MRI screening of family members may be considered.


9. Diagnosis

In patients with suspected intracerebral hemorrhage, non-contrast head CT is the standard test for emergency diagnosis. CT offers short scan time, high accessibility, and high sensitivity for ICH (nearly 100%), making it essential in the initial emergency department assessment. A hyperdense intraparenchymal lesion on CT indicates ICH, and hematoma size is calculated with the ABC/2 formula or by automated computer measurement. The 'spot sign' or satellite lesions within the hematoma are identified on CTA and are important imaging biomarkers for predicting hematoma expansion.

In addition to predicting hematoma expansion, CT angiography (CTA) is used to rapidly evaluate causes of secondary ICH such as vascular malformations (AVM, cavernous malformation), aneurysms, and venous sinus thrombosis. Differentiation of secondary vascular lesions is particularly important in young patients, non-hypertensive patients, and those with lobar or atypically located hemorrhage. MRI is excellent for assessing temporal changes in the hematoma (hyperacute to chronic stage), surrounding edema, signs of CAA (cortical superficial siderosis, microbleed), and small vessel disease burden (periventricular leukoaraiosis), and is also useful for differentiating secondary brain tumors.

For blood tests, coagulation studies (PT/INR, aPTT, platelet count), blood glucose, electrolytes, renal function, and CBC are essential in the initial evaluation, and anticoagulant-specific tests (anti-Xa, thrombin time) may be added depending on anticoagulant use. ECG and echocardiography are performed to differentiate atrial fibrillation and cardiogenic causes. Brain amyloid PET or CSF amyloid testing is used for research purposes in the diagnosis of CAA but is not yet standardized in routine clinical practice. The Boston criteria v2.0, revised in 2017, are the clinical-imaging standard for CAA diagnosis and classify possible, probable, and definite CAA based on MRI SWI findings.


10. Treatment

Acute treatment of intracerebral hemorrhage aims to prevent hematoma expansion and minimize secondary injury. Acute blood pressure control is one of the most important treatments; the INTERACT2 study (2013) showed that intensive blood pressure control lowering systolic blood pressure to below 140 mmHg within 1 hour can limit hematoma expansion and improve functional recovery. The 2022 AHA/ASA guideline recommends treatment with a systolic blood pressure target of 150 mmHg (excluding SBP above 220 mmHg), with gradual blood pressure control using intravenous agents (labetalol, nicardipine, clevidipine).

In anticoagulant-related ICH, anticoagulation reversal is performed as emergency treatment. In warfarin-related ICH, four-factor prothrombin complex concentrate (4F-PCC) is preferred because it corrects the INR faster than FFP. In dabigatran-related ICH, the specific reversal agent idarucizumab can be used, and in rivaroxaban- and apixaban-related ICH, andexanet alfa can be used. Platelet transfusion is necessary when platelet count is reduced or platelet function is impaired.

Surgical hematoma evacuation remains controversial in ICH treatment but is performed selectively in certain patient groups. Emergency surgery is strongly recommended for cerebellar hemorrhage (diameter 3 cm or more, decreased GCS, accompanying hydrocephalus). Putaminal and lobar hemorrhages are considered for surgery when the hematoma is large (30 mL or more), the patient is young, and neurological deterioration is progressing, but the STICH study did not clearly prove a benefit of early craniotomy. Recently, minimally invasive hematoma evacuation (minimally invasive surgery with thrombolysis, MISTIE III) has been studied but has not yet been established as standard treatment. When intraventricular hemorrhage and hydrocephalus are present, external ventricular drainage (EVD) together with intraventricular tPA infusion (CLEAR III study) is performed in some patients.


11. Prognosis

Intracerebral hemorrhage is the stroke type with the worst prognosis, with 30-day mortality reaching about 35–52%. One-year mortality is about 50–60%, and only about 30–40% of survivors regain independent function. The most widely used tool for predicting ICH prognosis is the ICH Score, consisting of five items: GCS score, hematoma volume (over 30 mL), presence of intraventricular hemorrhage, infratentorial origin, and age (80 years or older). With an ICH Score of 0–1, 30-day mortality is 0–13%, whereas with 5–6 points it reaches 80–100%.

Hematoma expansion is the single most important factor in worsening prognosis; when the hematoma grows by 33% or more or by 6 mL or more, mortality and disability rates increase significantly. Accompanying intraventricular hemorrhage independently increases 30-day mortality about 2-fold, and prompt treatment of hydrocephalus is important for improving prognosis. Fever, hyperglycemia, and hypoxemia are secondary factors that worsen prognosis and require active management. Anticoagulant-related ICH shows higher mortality and a greater risk of hematoma expansion than spontaneous ICH.

In long-term prognosis, the risk of intracerebral hemorrhage recurrence differs by cause. After hypertensive ICH, the annual recurrence rate is about 2–4% when blood pressure is adequately controlled, but higher when uncontrolled. The annual recurrence rate of CAA-related ICH is high at about 5–10%, and higher in APOE ε4/ε4 homozygotes. Neurocognitive decline, depression, epilepsy, gait disturbance, and increased fall risk appear as long-term complications, and multidisciplinary rehabilitation plays a key role in functional recovery.


12. Prevention

The key to preventing intracerebral hemorrhage is aggressive treatment of hypertension. Maintaining systolic blood pressure below 130 mmHg significantly lowers the risk of ICH, and this is one of the most important goals of hypertension treatment guidelines. A low-salt diet, weight loss, regular aerobic exercise (at least 5 times a week, 30 minutes or more), and smoking cessation are non-pharmacological methods that contribute to blood pressure control. When hypertension is diagnosed, antihypertensive agents such as ACE inhibitors, ARBs, calcium channel blockers, and diuretics are prescribed according to the patient's living circumstances.

Smoking cessation is a key behavior for preventing stroke, including ICH. Smoking increases vascular fragility, raises blood pressure, and promotes platelet aggregation, increasing ICH risk. Moderation of alcohol intake is also important; heavy drinking raises ICH risk through increased blood pressure, reduced coagulation factors, and increased fall risk. In patients using anticoagulants, bleeding and thrombotic risks should be continuously reassessed, and excessive anticoagulation beyond what is necessary should be avoided. In elderly patients at high risk of falls, anticoagulants should be used with even greater caution, and fall prevention education and environmental modifications are needed.

For preventing recurrence in ICH survivors, intensified blood pressure control along with limiting alcohol intake and reassessing anticoagulant use are key. After CAA-related ICH, anticoagulant use is mostly contraindicated because of the high risk of recurrent cerebral hemorrhage, and antiplatelet agents are also decided on carefully. After hypertensive ICH, the timing of resuming antiplatelet agents and whether to resume anticoagulants are decided by individually assessing thromboembolic and bleeding risks. The 2022 AHA/ASA guideline suggests considering percutaneous left atrial appendage occlusion as an alternative to anticoagulation in ICH patients with nonvalvular atrial fibrillation who are at high risk of recurrent intracerebral hemorrhage.


13. References

  1. Greenberg SM, Ziai WC, Cordonnier C, et al. 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2022;53(7):e282-e361. DOI: 10.1161/STR.0000000000000407. PMID: 35579034.

  2. Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368(25):2355-2365. DOI: 10.1056/NEJMoa1214609. PMID: 23713578.

  3. van Asch CJ, Luitse MJ, Rinkel GJ, et al. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010;9(2):167-176. DOI: 10.1016/S1474-4422(09)70340-0. PMID: 20056489.

  4. Fiebach JB, Schellinger PD, Gass A, et al. Stroke magnetic resonance imaging is accurate in hyperacute intracerebral hemorrhage: a multicenter study on the validity of stroke imaging. Stroke. 2004;35(2):502-506. DOI: 10.1161/01.STR.0000114203.75678.73. PMID: 14739415.

  5. Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015;46(7):2032-2060. DOI: 10.1161/STR.0000000000000069. PMID: 26022637.

  6. Mendelow AD, Gregson BA, Fernandes HM, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet. 2005;365(9457):387-397. DOI: 10.1016/S0140-6736(05)17826-X. PMID: 15680453.

  7. Biffi A, Greenberg SM. Cerebral amyloid angiopathy: a systematic review. J Clin Neurol. 2011;7(1):1-9. DOI: 10.3988/jcn.2011.7.1.1. PMID: 21519520.

  8. Sacco S, Marini C, Toni D, et al. Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry. Stroke. 2009;40(2):394-399. DOI: 10.1161/STROKEAHA.108.523209. PMID: 19008468.

  9. Kim BJ, Han MK, Park TH, et al. Current status of acute stroke management in Korea: a report on a multicenter, comprehensive stroke registry. Int J Stroke. 2014;9(4):514-518. DOI: 10.1111/ijs.12123. PMID: 23879752.

  10. Broderick JP, Brott T, Tomsick T, et al. Ultra-early evaluation of intracerebral hemorrhage. J Neurosurg. 1990;72(2):195-199. DOI: 10.3171/jns.1990.72.2.0195. PMID: 2299229.